Lipocine Highlights Its Partner, Antares Pharma, Reported FDA Accepted Its New Drug Application Resubmission For TLANDO
Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that Antares Pharma, Inc. issued a press release
Lipocine Q3 EPS $(0.03) Up From $(0.07) YoY
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year.
18 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced plans to launch distribution of its products in the U.K.
Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
Lipocine Inc (NASDAQ:LPCN) has entered into an exclusive licensing agreement with Antares Pharma Inc (NASDAQ:ATRS) to commercialize Tlando in the U.S. Tlando is…
Lipocine and Antares Pharma Enter Into a Licensing Agreement to Commercialize TLANDO, Lipocine to Receive $11M Upfront and Up to $170M in the Future
Under the terms of Agreement Lipocine to receive:
Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0 million to be paid in the future subject to
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)